NCT04609891 is a NA clinical trial of Avatrombopag in Thrombocytopenia, sponsored by Anhui Provincial Cancer Hospital.

Who is sponsoring NCT04609891?

NCT04609891 is sponsored by Anhui Provincial Cancer Hospital.

What drugs are being tested in NCT04609891?

Interventions in NCT04609891: Avatrombopag.

What condition does NCT04609891 study?

NCT04609891 studies Thrombocytopenia.

Is NCT04609891 still recruiting?

NCT04609891 is currently completed. Last updated 29 April 2022.

Last reviewed 2022-04-29 · How we verify

NCT04609891

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Avatrombopag on the Treatment of Thrombocytopenia Induced by Chemotherapy of Malignant Tumors

Completed NA Last updated 29 April 2022

What this trial tests

NA trial testing Avatrombopag in Thrombocytopenia in 74 participants. Completed in 16 May 2021.

Timeline

26 May 2020

Primary endpoint
16 May 2021

16 May 2021

Quick facts

Lead sponsor	Anhui Provincial Cancer Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	74
Start date	26 May 2020
Primary completion	16 May 2021
Estimated completion	16 May 2021
Sites	1 location across China

Drugs / interventions tested

Avatrombopag (AVATROMBOPAG) — full drug profile →

Conditions studied

Thrombocytopenia — all drugs for Thrombocytopenia →

Sponsor

Anhui Provincial Cancer Hospital

Who can join

Adults 18 to 75, any sex, with Thrombocytopenia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To observe the clinical efficacy and safety of avatrombopag for chemotherapy-induced thrombocytopenia in patients with malignant tumors.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists.
Gilreath J, Lo M, Bubalo J. · · 2021 · cited 73× · PMID 34160821 · DOI 10.1007/s40265-021-01553-7
Challenges and Advances in Managing Thrombocytopenic Cancer Patients.
Leader A, Hofstetter L, Spectre G. · · 2021 · cited 23× · PMID 33799591 · DOI 10.3390/jcm10061169
Avatrombopag for the treatment of thrombocytopenia induced by chemotherapy in patients with solid tumors: A multicenter, open-label, single-arm trial.
Cui Y, He Y, Hu C, Tu C, et al · · 2022 · cited 11× · PMID 36238568 · DOI 10.3389/fphar.2022.970978

Verify or expand the search:

Other trials of Avatrombopag

Trials testing the same drug.

NCT07051915 — The Holistic Study · Phase 3 · not yet recruiting
NCT06254287 — Efficacy and Safety of Avatrombopag vs. Avatrombopag Combined With rhTPO in the Treatment of SAA · Phase 2 · unknown
NCT05772546 — Avatrombopag vs. Placebo for CIT in GI Malignancies · Phase 2 · active not recruiting
NCT05996393 — CsA+ATG+AVA vs. CsA+AVA for the Treatment of Newly-diagnosed SAA in the Elderly · Phase 4 · completed
NCT06001567 — Avatrombopag for HCC Patients With Thrombocytopenia Who Intend to Undergo TACE and/or HAIC · Phase 2 · unknown

Other recruiting trials for Thrombocytopenia

Currently open trials in the same condition.

NCT07441720 — Safety and Efficacy of Umbilical Cord Blood Therapy for Cancer Therapy-Induced Thrombocytopenia (CTIT) · Phase 2 · recruiting
NCT07442513 — Comparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT · Phase 3 · recruiting
NCT07257809 — Herombopag Treated T-DM1 Induced Platelet Reduction · Phase 2 · recruiting
NCT06676904 — Neonatal Platelet Transfusion Threshold Trial · NA · recruiting
NCT06886516 — Apixaban in Thrombocytopenia · EARLY_PHASE1 · recruiting

Other Anhui Provincial Cancer Hospital trials

Trials by the same sponsor.

NCT07371871 — A Prospective, Single-arm, Exploratory Study of Trifluridine/Tipiracil (TAS-102) Combined With Apatinib as Third-line Th · NA · not yet recruiting
NCT07299890 — An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy · Phase 2 · not yet recruiting
NCT07330596 — QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC · Phase 2 · recruiting
NCT07197697 — A Phase II Exploratory Study of Iparomlimab and Tuvonralimab Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ · Phase 2 · not yet recruiting
NCT07195084 — To Explore the Safety and Efficacy of Hypervision Proton Surgery for Early-stage Non-small Cell Lung Cancer · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04609891 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Anhui Provincial Cancer Hospital
Last refreshed: 29 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04609891.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing